Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.
Biologicals
; 35(1): 35-42, 2007 Mar.
Article
em En
| MEDLINE
| ID: mdl-16581263
Patients with immunodeficiencies or some types of autoimmune diseases rely on a safe therapy with intravenous immunoglobulins (IVIGs) manufactured from human plasma, the only available source for this therapeutic. Since plasma is predisposed to contamination by a variety of blood-borne pathogens, ascertaining and ensuring the pathogen safety of plasma-derived therapeutics is a priority among manufacturers. State-of-the-art manufacturing processes provide a high safety standard by incorporating virus elimination procedures into the manufacturing process. Based on their mechanism these procedures are grouped into three classes: partitioning, inactivation, and virusfiltration.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Vírus
/
Imunoglobulinas Intravenosas
Limite:
Humans
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article